NASDAQ:ONC Beigene (ONC) Stock Price, News & Analysis $255.77 +0.13 (+0.05%) As of 05/2/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock About Beigene Stock (NASDAQ:ONC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Beigene alerts:Sign Up Key Stats Today's Range$254.37▼$262.7650-Day Range$206.32▼$278.3852-Week Range$141.31▼$287.88Volume180,351 shsAverage Volume478,851 shsMarket Capitalization$25.30 billionP/E RatioN/ADividend YieldN/APrice Target$318.88Consensus RatingBuy Company OverviewBeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.Read More… Beigene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreONC MarketRank™: Beigene scored higher than 40% of companies evaluated by MarketBeat, and ranked 613th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBeigene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBeigene has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Beigene's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Beigene are expected to grow in the coming year, from ($5.82) to $0.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Beigene is -31.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Beigene is -31.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioBeigene has a PEG Ratio of 7.73. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBeigene has a P/B Ratio of 6.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ONC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeigene does not currently pay a dividend.Dividend GrowthBeigene does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ONC. News and Social Media1.7 / 5News Sentiment0.08 News SentimentBeigene has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Beigene this week, compared to 8 articles on an average week.Search InterestOnly 2 people have searched for ONC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Beigene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $295,198,300.00 in company stock.Percentage Held by InsidersOnly 6.62% of the stock of Beigene is held by insiders.Percentage Held by Institutions48.55% of the stock of Beigene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Beigene's insider trading history. Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Beigene and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Stock News HeadlinesLeerink Partnrs Forecasts Beigene's Q1 Earnings (NASDAQ:ONC)May 2 at 1:21 AM | americanbankingnews.comBeiGene gewinnt US-Patentstreit über KrebsmedikamentMay 1 at 12:57 PM | de.investing.comBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.May 3, 2025 | Crypto 101 Media (Ad)US-amerikanisches Patent- und Markenamt erklärt das gegen BeiGene geltend gemachte Pharmacyclics-Patent für ungültigMay 1 at 12:57 PM | de.finance.yahoo.comU.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGeneApril 29, 2025 | businesswire.com3 Stocks That Could Be Trading Below Their Estimated Fair ValueApril 29, 2025 | uk.finance.yahoo.comBeigene's (ONC) Outperform Rating Reaffirmed at Royal Bank of CanadaApril 29, 2025 | americanbankingnews.comAnalysts Set Beigene, Ltd. (NASDAQ:ONC) Target Price at $316.71April 27, 2025 | americanbankingnews.comSee More Headlines ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? Beigene's stock was trading at $223.50 at the start of the year. Since then, ONC stock has increased by 14.4% and is now trading at $255.77. View the best growth stocks for 2025 here. How were Beigene's earnings last quarter? Beigene, Ltd. (NASDAQ:ONC) posted its quarterly earnings data on Thursday, February, 27th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.88) by $0.55. The business earned $1.13 billion during the quarter, compared to the consensus estimate of $1.09 billion. Beigene had a negative trailing twelve-month return on equity of 25.12% and a negative net margin of 25.94%. How do I buy shares of Beigene? Shares of ONC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/27/2025Today5/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONC Previous SymbolNASDAQ:ONC CIK1651308 WebN/A Phone13459494123FaxN/AEmployees9,000Year FoundedN/APrice Target and Rating Average Stock Price Target$318.88 High Stock Price Target$348.00 Low Stock Price Target$259.00 Potential Upside/Downside+24.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($6.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth7.73Net Income$-881,710,000.00 Net Margins-25.94% Pretax Margin-24.07% Return on Equity-25.12% Return on Assets-14.95% Debt Debt-to-Equity Ratio0.05 Current Ratio1.93 Quick Ratio1.72 Sales & Book Value Annual Sales$3.81 billion Price / Sales6.64 Cash FlowN/A Price / Cash FlowN/A Book Value$37.10 per share Price / Book6.89Miscellaneous Outstanding Shares98,911,000Free Float90,588,000Market Cap$25.30 billion OptionableN/A Beta0.49 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ONC) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredReal Americans Don’t Wait on Wall Street’s Next MoveWhat's happening in the markets right now should concern every freedom-loving American who's worked hard and s...Premier Gold Co | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Beigene, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Beigene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.